David Shaywitz

Architects and Gardeners Most leadership offsites I’ve attended have included some flavor of personality assessment – not so much to formally classify us, but rather to make the point that different people have different styles, and to emphasize that you can’t assume everyone you work with approaches the world the same way you do.  In this spirit, I wanted to... Read More

I can’t stop thinking about a recent series of poignant blog posts, written by an emergency room physician affiliated with the Mayo Clinic. Her husband has been battling a terrible cancer – recurrent/metastatic head and neck squamous cell carcinoma.  Given what she does for a living, the author, Dr. Bess Stillman, is about as well-positioned to be a savvy patient... Read More

My Ground Truth Every other week, I stroll across the Longfellow Bridge from Cambridge to Boston. It can be a magnificent walk in the fall and spring, when the weather is temperate and the skies clear. You can see the deep blue of the Charles River, the Esplanade on your left, with the Boston skyline behind it, and the Citgo... Read More

Two recent Wall Street Journal deep-dives nicely bookend a critical, and unresolved, tension faced by large pharmaceutical companies: how can their R&D organizations discover, develop, and deliver the new medicines patients await, and the growth and return on investment that shareholders demand? Early this year, I discussed an April 2023 profile of Lilly by journalist Peter Loftus, who described how the company, led by a physician-scientist... Read More

Generative AI, the transformative technology of the moment, exploded onto the scene with the arrival in late 2022 of chatGPT, an AI-powered chatbot developed by the company OpenAI.  After only five days, a million users had tried the app; after two months: 100 million, the fastest growth ever seen for a consumer application. TikTok, the previous record holder, took nine... Read More

As the excitement around generative AI sweeps across the globe, biopharma R&D groups (like most everyone else) are actively trying to figure out how to leverage this powerful but nascent technology effectively, and in a responsible fashion. In separate conversations, two prominent pharma R&D executives recently sat down with savvy healthtech VCs to discuss how generative AI specifically, and emerging... Read More

Today, we’ll begin with a consideration of the promise for AI some experts see in healthcare and biopharma. Next, we’ll look at some of the obstacles – some technical, some organizational – and re-visit the eternal “data parasite” debate. Finally, we’ll conclude with a few suggestions for summer reading. The AI Opportunity: Elevating Healthcare for All Earlier this month, I... Read More

Biopharma relies on innovation to stay in business. Success depends on our collective ability to discover, develop, and deliver new products that cure or meaningfully mitigate disease over and over again. Patents allow for innovators to be rewarded, for a while. When patents expire, allowing us to purchase powerful generic medications like atorvastatin for pennies, manufacturers must come up with... Read More

The worlds of technology and entrepreneurship are captivated by recent advances in generative AI and large language models (LLMs).  The arrival of ChatGPT, developed by OpenAI (a startup partnered with Microsoft), caused Google to declare a “Code Red,” akin to “pulling the fire alarm,” the New York Times explained. The latest class of startups at Y Combinator are reportedly flocking... Read More

In 1935, Astounding Science — the premier science fiction magazine of the day, and perhaps ever — published “Proxima Centauri.” It was a short story envisioning an encounter between a voyaging earth spacecraft and a ship from a nearby star system. Written by Murray Leinster (William Fitzgerald Jenkins), the tale features the original use of the phrase “first contact” in... Read More

Biopharma, like the rest of the world, appears to be on the threshold of profound, technology-induced change. Incredible advances in artificial intelligence, manifested most recently in GPT-4, are here.  This technology, Ezra Klein explains in the New York Times, “changes everything.”  Bill Gates describes it as “the most important advance in technology since the graphical user interface,” and declares, “the... Read More

The success or failure of many technology platforms — including in particular health tech platforms — rests with a largely obscure role of outsized importance: the “solutions engineer.”  The role itself goes by many names. Back when I was at DNAnexus in the mid-2010s, this role was called “Solutions Scientist.” Others call it “Forward-Deployed Engineer” or “Embedded Analyst.” Whatever the... Read More

Most biopharma companies have started down the path of digital transformation – a fundamental overhaul of everything they do for the digital age. It’s not clear yet that anyone has arrived at the desired destination. Even so, there have been some early wins, generally related to operations, as the CEOs of both Novartis and Lilly have described. Arguably, the most... Read More

In 1845, dentist Horace Wells stood before Harvard medical students and faculty, eager to demonstrate the utility of nitrous oxide – laughing gas – as a general anesthetic.  Wells tried it out on a patient who needed  a tooth extraction. The dose, it turned out, wasn’t enough. The patient screamed in agony.  As described by Paul Offit in You Bet... Read More

For today: topics relevant to many drug developers (and others): The initial impact of digital The dilemma of data collection in early clinical studies The elusive search for “new normal” ways of working Initial impact of digital in biopharma The sexy promise of digital/data/AI in biopharma was that emerging digital technologies were going to solve our most important and vexing... Read More

Searching for a good listen or an interesting read? Here are my latest suggestions. Everything is awesome! Looking for something thoughtful and uplifting? A great place to start is this recent interview with tech VC Marc Andreessen, who discusses, persuasively, why he is still so optimistic about technology. Particularly useful: Andreessen’s ability to contextualize the evolution of technology, including the... Read More

Drug development remains an incredibly expensive endeavor. Much of the cost can be attributed to late-stage clinical trial failures.  The burden is borne first and foremost by clinical trial participants who aren’t helped by the experimental medicine. It also significantly impacts the companies sponsoring these studies. Everyone would like to improve the chances that a novel medicine that advances into... Read More

The implementation of emerging technologies requires front-line users to figure out what to do with the technology – how to adapt the technology to the problems users are actively trying to solve.    The most impactful use cases often are not immediately obvious – for example, Edison envisioned the phonograph would be predominantly used to record wills.    Moreover, effective adoption typically requires... Read More